We are live on ! Find out more
Prosight Management

Prosight Management Portfolio holdings

AUM $515M Turnover 48.89%
1-Year Est. Return 2.95%
This Fund
S&P 500
This Quarter Est. Return
+24.97%
1 Year Est. Return
-2.95%
3 Year Est. Return
+53.41%
5 Year Est. Return
-10.05%
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$18.7M
Cap. Flow
-$71.7M
Cap. Flow %
-16.72%
Top 10 Hldgs %
55.8%
Holding
50
New
11
Increased
13
Reduced
18
Closed
8
Avg Time Held Equity + Options
1 year
Top 10 Avg Time Held Equity + Options
1.2 years
Top 20 Avg Time Held Equity + Options
1.1 years
Avg Time Held Equity only
1 year
Top 10 Avg Time Held Equity only
1.2 years
Top 20 Avg Time Held Equity only
1.1 years

Sector Composition

Rank Sector Weight
1 Healthcare 97.02%
2 Miscellaneous 2.86%
3 Industrials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
LKFT icon
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.18B
$39.8M 9.29%
1,150,000
-623,649
-35% -$20M
2021 Q1
18 quarters
MGTX icon
2
MeiraGTx Holdings
MGTX
$780M
$33.7M 7.85%
4,089,509
-497,914
-11% -$3.94M
2022 Q1
14 quarters
ADCT icon
3
ADC Therapeutics
ADCT
$180M
$29.9M 6.97%
7,472,303
-2,995,468
-29% -$9.44M
2022 Q3
12 quarters
KURA icon
4
Kura Oncology
KURA
$635M
$24.4M 5.69%
2,758,516
-422,668
-13% -$3.01M
2023 Q2
9 quarters
ISRG icon
5
Intuitive Surgical
ISRG
$138B
$21.8M 5.08%
+48,711
New +$23.4M
2025 Q3
0 quarters
JANX icon
6
Janux Therapeutics
JANX
$617M
$21.1M 4.93%
865,350
+11,446
+1% +$279K
2024 Q3
4 quarters
ROIV icon
7
Roivant Sciences
ROIV
$28B
$20.2M 4.71%
1,335,500
-473,039
-26% -$5.86M
2024 Q1
6 quarters
ICLR icon
8
Icon
ICLR
$14B
$19.2M 4.47%
109,500
+10,942
+11% +$1.83M
2024 Q4
3 quarters
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$785M
$15.4M 3.6%
1,003,400
-76,273
-7% -$998K
2024 Q2
5 quarters
BBIO icon
10
BridgeBio Pharma
BBIO
$14.8B
$13.7M 3.2%
264,500
-208,187
-44% -$10.2M
2024 Q1
6 quarters
CRNX icon
11
DELISTED
Crinetics Pharmaceuticals
CRNX
$13.7M 3.19%
328,684
+30,561
+10% +$977K
2025 Q2
1 quarter
FOLD icon
12
DELISTED
Amicus Therapeutics
FOLD
$13.5M 3.14%
1,709,533
-1,770,511
-51% -$12.6M
2024 Q4
3 quarters
DXCM icon
13
DexCom
DXCM
$29.6B
$13.1M 3.06%
195,217
+125,217
+179% +$9.9M
2025 Q2
1 quarter
STTK icon
14
Shattuck Labs
STTK
$454M
$13M 3.04%
5,451,195
-1,187,740
-18% -$1.45M
2021 Q3
16 quarters
ZYME icon
15
Zymeworks
ZYME
$1.81B
$12.8M 2.99%
749,611
-560,293
-43% -$8.02M
2024 Q1
6 quarters
CON icon
16
Concentra Group Holdings
CON
$5.26B
$12.8M 2.98%
610,000
+297,895
+95% +$6.35M
2025 Q2
1 quarter
CORT icon
17
CALL
Corcept Therapeutics
CORT
$6.88B
$12.3M 2.86%
+147,800
New +$10.7M
2025 Q3
0 quarters
IMVT icon
18
Immunovant
IMVT
$6.57B
$11.3M 2.63%
698,472
+219,072
+46% +$3.55M
2024 Q1
6 quarters
SEM icon
19
DELISTED
Select Medical
SEM
$11.2M 2.62%
874,915
+521,095
+147% +$6.94M
2025 Q2
1 quarter
BHVN icon
20
Biohaven
BHVN
$1.87B
$9.01M 2.1%
600,000
+60,929
+11% +$887K
2025 Q1
2 quarters
VRTX icon
21
Vertex Pharmaceuticals
VRTX
$131B
$8.03M 1.87%
+20,500
New +$8.57M
2025 Q3
0 quarters
BSX icon
22
Boston Scientific
BSX
$60.8B
$7.43M 1.73%
+76,100
New +$7.88M
2025 Q3
0 quarters
CDNA icon
23
CareDx
CDNA
$3.68B
$7.33M 1.71%
504,030
+201,222
+66% +$2.87M
2024 Q4
3 quarters
ACHC icon
24
Acadia Healthcare
ACHC
$3.22B
$6.19M 1.44%
250,000
+38,184
+18% +$852K
2024 Q3
4 quarters
TECX icon
25
Tectonic Therapeutic
TECX
$405M
$5.95M 1.39%
379,254
-62,802
-14% -$1.3M
2025 Q1
2 quarters

Similar funds

Prosight Management's Q3 2025 Portfolio in Review

As of Q3 2025, Prosight Management held 50 positions worth $429M, up 4.6% from $410M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Prosight Management withdrew a net $71.7M in Q3 2025, closing 8 positions and reducing 18 holdings. Its most notable exit was UnitedHealth, an estimated $34.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Prosight Management opened a new position in Intuitive Surgical worth $21.8M.

  • Prosight Management's largest Q3 2025 buy was Intuitive Surgical: 48,711 shares worth $21.8M.
  • Prosight Management added most to DexCom in Q3 2025, an estimated $9.9M increase.
  • Prosight Management's biggest Q3 2025 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $20M.
  • Prosight Management fully exited UnitedHealth in Q3 2025, selling an estimated $34.3M.
  • Prosight Management's ten largest holdings make up 56% of its $429M portfolio in Q3 2025.
  • Prosight Management opened 11 new positions and closed 8 in Q3 2025.
  • Prosight Management's portfolio value rose 4.6% quarter-over-quarter to $429M.

Based on Prosight Management's 13F filing for Q3 2025, filed 14 Nov 2025.